Cargando…

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed or refractory diffuse large B-cell lymphoma who had previously received rituxi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trnĕný, Marek, Verhoef, Gregor, Dyer, Martin JS, Ben Yehuda, Dina, Patti, Caterina, Canales, Miguel, Lopez, Andrés, Awan, Farrukh T, Montgomery, Paul G, Janikova, Andrea, Barbui, Anna M, Sulek, Kazimierz, Terol, Maria J, Radford, John, Guidetti, Anna, Di Nicola, Massimo, Siraudin, Laure, Hatteville, Laurence, Schwab, Sandrine, Oprea, Corina, Gianni, Alessandro M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068033/ https://www.ncbi.nlm.nih.gov/pubmed/29748443 http://dx.doi.org/10.3324/haematol.2017.168401

Ejemplares similares

Targeting CD19 in B-cell lymphoma: emerging role of SAR3419
por: Raufi, Ali, et al.
Publicado: (2013)

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
por: Schönfeld, Kurt, et al.
Publicado: (2017)

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
por: Schönfeld, Kurt, et al.
Publicado: (2018)

Patients' and families' opinions via suggestion boxes for improving hospital care for cancer patients: Analysis of 3419 cases over 11 years
por: Takao, Kenji, et al.
Publicado: (2021)

Correction: Dueñas et al. Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals. Cancers 2020, 12, 3419
por: Dueñas, Nuria, et al.
Publicado: (2021)

Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study
por: Pouzin, Clemence, et al.
Publicado: (2022)

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
por: Tabernero, Josep, et al.
Publicado: (2023)

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
por: Quanz, Maria, et al.
Publicado: (2018)

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
por: Pouzin, Clemence, et al.
Publicado: (2022)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
por: Hassan, Raffit, et al.
Publicado: (2020)

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
por: Hicks, Stuart W., et al.
Publicado: (2019)

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
por: Santin, Alessandro D, et al.
Publicado: (2023)

Analysis of Argyrophilic Nucleolar Organizer Regions (AgNORs) in Acute Leukemia in Adults
por: Gajewska, Małgorzata, et al.
Publicado: (2022)

AgNOR patterns and configurations in adult acute leukemia patients
por: Gajewska, Małgorzata, et al.
Publicado: (2023)

A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent
por: Procházka, Vít, et al.
Publicado: (2014)

Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry
por: Mocikova, Heidi, et al.
Publicado: (2022)

The Effect of Liquid Crystalline Structures on Antiseizure Properties of Aqueous Solutions of Ethoxylated Alcohols
por: Sulek, Marian Wlodzimierz, et al.
Publicado: (2010)

The Effect of Endurance Training on Brain-Derived Neurotrophic Factor and Inflammatory Markers in Healthy People and Parkinson's Disease. A Narrative Review
por: Małczyńska-Sims, Paulina, et al.
Publicado: (2020)

Editorial: PTCL from genes to therapy
por: Janikova, Andrea
Publicado: (2022)

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic
por: Obr, Ales, et al.
Publicado: (2022)

Ecological Cutting Fluids
por: Sułek, Marian Włodzimierz, et al.
Publicado: (2020)

High relative frequency of SCA1 in Poland reflecting a potential founder effect
por: Krysa, Wioletta, et al.
Publicado: (2016)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Impaired Kidney Function Associated with Increased Risk of Side Effects in Patients with Small Vessel Vasculitis Treated with Rituximab as an Induction Therapy
por: Rymarz, Aleksandra, et al.
Publicado: (2021)

High-intensity interval training modulates inflammatory response in Parkinson’s disease
por: Malczynska-Sims, Paulina, et al.
Publicado: (2022)

Correction: High-intensity interval training modulates inflammatory response in Parkinson’s disease
por: Malczynska-Sims, Paulina, et al.
Publicado: (2022)

Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis
por: Bighelli, Irene, et al.
Publicado: (2017)

Adaptation and validation of the Physical Activity Questionnaire for Older Children (PAQ-C) among Czech children
por: Cuberek, Roman, et al.
Publicado: (2021)

Characterization of SCIT Induced Anaphylaxis Pre and Post Pandemic: Did COVID Make An Impact?
por: Oprea, Anna, et al.
Publicado: (2023)

An extended best–worst multiple reference point method: application in the assessment of non-life insurance companies
por: Bilbao-Terol, Amelia, et al.
Publicado: (2022)

Is investing in the renewable energy stock market both financially and ESG efficient? A COVID-19 pandemic analysis
por: Bilbao-Terol, Amelia, et al.
Publicado: (2023)

Genes Associated with Biological Nitrogen Fixation Efficiency Identified Using RNA Sequencing in Red Clover (Trifolium pratense L.)
por: Vlk, David, et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
por: Lobello, Cosimo, et al.
Publicado: (2018)

Chronic Benign CD8+ Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse
por: Osovská, Marcela, et al.
Publicado: (2019)

Nurses’ Perceptions of Professional Practice Environment and Its Relation to Missed Nursing Care and Nurse Satisfaction
por: Zeleníková, Renáta, et al.
Publicado: (2020)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

The Undoped Polycrystalline Diamond Film—Electrical Transport Properties
por: Łoś, Szymon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8l99o4heb5nj1gpnii4n542h0d